KR20240021217A - 톨레브루티닙의 결정질 형태 및 이의 제조 방법 및 용도 - Google Patents

톨레브루티닙의 결정질 형태 및 이의 제조 방법 및 용도 Download PDF

Info

Publication number
KR20240021217A
KR20240021217A KR1020247000650A KR20247000650A KR20240021217A KR 20240021217 A KR20240021217 A KR 20240021217A KR 1020247000650 A KR1020247000650 A KR 1020247000650A KR 20247000650 A KR20247000650 A KR 20247000650A KR 20240021217 A KR20240021217 A KR 20240021217A
Authority
KR
South Korea
Prior art keywords
crystalline form
compound
crystalline
csiii
csiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247000650A
Other languages
English (en)
Korean (ko)
Inventor
민화 천
쟈밍 스
징 장
Original Assignee
젠자임 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 젠자임 코포레이션 filed Critical 젠자임 코포레이션
Publication of KR20240021217A publication Critical patent/KR20240021217A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020247000650A 2021-06-11 2022-06-02 톨레브루티닙의 결정질 형태 및 이의 제조 방법 및 용도 Pending KR20240021217A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202110652005.2 2021-06-11
CN202110652005 2021-06-11
CN202110690510.6 2021-06-22
CN202110690510 2021-06-22
CN202111326112.2 2021-11-10
CN202111326112 2021-11-10
PCT/CN2022/096779 WO2022257845A1 (zh) 2021-06-11 2022-06-02 Tolebrutinib的晶型及其制备方法和用途

Publications (1)

Publication Number Publication Date
KR20240021217A true KR20240021217A (ko) 2024-02-16

Family

ID=84425691

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247000650A Pending KR20240021217A (ko) 2021-06-11 2022-06-02 톨레브루티닙의 결정질 형태 및 이의 제조 방법 및 용도

Country Status (12)

Country Link
US (1) US20250034130A1 (https=)
EP (1) EP4353723A4 (https=)
JP (1) JP2024521412A (https=)
KR (1) KR20240021217A (https=)
CN (1) CN117897381A (https=)
AU (1) AU2022290946A1 (https=)
BR (1) BR112023025841A2 (https=)
CA (1) CA3221129A1 (https=)
CO (1) CO2024000054A2 (https=)
IL (1) IL309263A (https=)
MX (1) MX2023014722A (https=)
WO (1) WO2022257845A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021398051A1 (en) 2020-12-10 2023-07-27 Principia Biopharma Inc. Crystal form of tolebrutinib, preparation method therefor and use thereof
US20250145618A1 (en) * 2021-12-21 2025-05-08 Principia Biopharma Inc. Crystalline Forms of (R)-1-(1-Acryloylpiperidin-3-YL)-4-Amino-3-(4-Phenoxyphenyl)-1H-Imidazo[4,5-C]Pyridin-2(3H)-One and salts Thereof
WO2023172663A1 (en) 2022-03-09 2023-09-14 Teva Pharmaceuticals International Gmbh Solid state forms of tolebrutinib and of tolebrutinib salts
AU2023408758A1 (en) * 2022-12-20 2025-07-31 Principia Biopharma Inc. Drug formulations of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4- phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one
WO2026050513A1 (en) 2024-08-30 2026-03-05 Principia Biopharma Inc. Tolebrutinib for multiple sclerosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2004001034A1 (es) * 2003-05-14 2005-03-28 Teijin Pharma Ltd Formas cristalinas de acido 4-(1-((,etilbenzotiofen-3-il)me til)benzimidazol-2-iltio)butanoico; procedimiento de preparacion de las formas cristalinas; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias, alergicas, r
UA124090C2 (uk) * 2015-06-03 2021-07-21 Прінсіпіа Байофарма Інк. Інгібітори тирозинкінази
CA2986790A1 (en) * 2015-06-26 2016-12-29 Aquinox Pharmaceuticals (Canada) Inc. Crystalline solid forms of the acetate salt of (1s,3s,4r)-4-((3as,4r,5s,7as)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1h-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanol
CN105753863B (zh) * 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
BR112022014058A2 (pt) * 2020-01-20 2022-09-13 Genzyme Corp Inibidores terapêuticos de tirosina cinase para esclerose múltipla recidivante (rms)

Also Published As

Publication number Publication date
EP4353723A4 (en) 2025-06-25
BR112023025841A2 (pt) 2024-03-05
EP4353723A1 (en) 2024-04-17
CO2024000054A2 (es) 2024-02-05
WO2022257845A1 (zh) 2022-12-15
CA3221129A1 (en) 2022-12-15
US20250034130A1 (en) 2025-01-30
CN117897381A (zh) 2024-04-16
MX2023014722A (es) 2024-02-13
AU2022290946A1 (en) 2024-01-25
JP2024521412A (ja) 2024-05-31
IL309263A (en) 2024-02-01

Similar Documents

Publication Publication Date Title
KR20240021217A (ko) 톨레브루티닙의 결정질 형태 및 이의 제조 방법 및 용도
KR102872880B1 (ko) 톨레브루티닙의 결정 형태, 이의 제조 방법 및 용도
US12428402B2 (en) Resmetirom crystal, preparation method for same, and uses thereof
KR20230153533A (ko) 유로리틴 유도체 및 이의 사용 방법
US11572365B2 (en) Crystal form of upadacitinib, preparation method therefor, and use thereof
US20210332014A1 (en) Cabozantinib malate crystal form, preparation method and use thereof
KR20150105313A (ko) N-(3-(4-(3-(디이소부틸아미노)프로필)피페라진-1-일)프로필)-1H-벤조[d]이미다졸-2-아민의 황산염들, 이들의 제조 방법 및 그것의 용도
CN114644642B (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
US20220185781A1 (en) Bulleyaconitine d crystal and preparation method therefor and application thereof
US20210363101A1 (en) Crystalline forms of gft-505, processes for preparation and use thereof
US11192882B2 (en) Crystal form of small molecule immune compound, preparation method thereof and pharmaceutical composition containing the same
US20260070919A1 (en) Crystal form of five-membered and six-membered heterocyclic compound, preparation method therefor, and use thereof
EP4056559A1 (en) Phenyl amino pyrimidine compound or polymorph of salt thereof
US10815232B2 (en) Crystalline forms of viral-protein inhibitor drug VX-787, processes for preparation thereof and use thereof
HK40111001A (en) Crystal form of tolebrutinib, preparation method therefor and use thereof
CA3087474A1 (en) Crystalline forms of acalabrutinib, processes for preparation and use thereof
WO2022256550A1 (en) Crystalline forms of an adenosine a2b receptor antagonist
HK40094757A (en) Crystal form of tolebrutinib, preparation method therefor and use thereof
KR20260027280A (ko) 박스드로스타트의 결정 형태, 및 이의 제조 방법 및 용도
CN118401513A (zh) 他伐帕敦的晶型及其制备方法和用途
JPH0368557A (ja) ビスべンジルイソキノリン誘導体
NZ748385A (en) Crystal forms of crisaborole in free form and preparation method and use thereof
CN106478608A (zh) 沃拉帕沙的硫酸盐的结晶多晶型物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000